Copper Bisglycinate — The Collagen Crosslinker

Copper functions as a catalytic cofactor for several cuproenzymes with direct relevance to aging and skin biology. Lysyl oxidase (LOX) requires copper to oxidise lysine residues in procollagen and proelastin, initiating the crosslinking that gives connective tissue its tensile strength and elasticity. Tyrosinase, another cuproenzyme, catalyses the rate-limiting step in melanin biosynthesis, determining hair and skin pigmentation. Copper-zinc superoxide dismutase (Cu/Zn-SOD) is a primary cytoplasmic antioxidant enzyme that dismutates superoxide radicals into hydrogen peroxide, protecting cells from oxidative damage. Copper also participates in mitochondrial electron transport via cytochrome c oxidase (Complex IV), linking it to cellular energy production. The bisglycinate chelate form protects copper from competitive inhibition by phytates and zinc in the gastrointestinal tract, resulting in significantly higher fractional absorption than copper sulphate or copper oxide.

Copper deficiency is well-documented to impair collagen crosslinking, leading to fragile connective tissue, anaemia, and neurological dysfunction. Supplementation trials in deficient populations consistently restore these parameters. In healthy adults, a 2020 randomised trial in the Journal of Trace Elements in Medicine and Biology demonstrated that copper bisglycinate at 2 mg/day significantly increased serum ceruloplasmin and erythrocyte Cu/Zn-SOD activity compared to copper sulphate, confirming superior bioavailability. Dedicated skin elasticity trials specifically using copper bisglycinate are limited, though the mechanistic evidence via lysyl oxidase is robust.

The RDA for copper is 900 µg/day for adults, with a tolerable upper intake level of 10 mg/day. Supplemental doses for connective tissue support typically range from 1–2 mg/day of elemental copper as bisglycinate. Copper should be balanced with zinc supplementation, as high zinc intake (>40 mg/day) can competitively inhibit copper absorption. Best taken with food to reduce gastrointestinal discomfort.

Copper toxicity is rare at supplemental doses below 10 mg/day. Acute toxicity presents as nausea, vomiting, and abdominal pain. Chronic excess copper accumulation can cause liver damage and, in genetically susceptible individuals (Wilson's disease), neurological and hepatic injury. Individuals with Wilson's disease must avoid copper supplementation entirely. Copper supplements should not be taken simultaneously with zinc supplements, as they compete for the same intestinal transporters.

Key Papers